Back to Trial

Oracle Runs

Oracle findings and outcome history for A Study to Evaluate the Efficacy and Safety of HSK31858 Tablets in Patients with Bronchial Asthma (NCT06637254).

Runs
5
Findings
5
Latest Run
Apr 6, 2026, 2:57 PM
All Oracle Findings

Every stored oracle finding for this trial, including pending, dismissed, rejected, superseded, and accepted items.

NO_DECISIONDismissed100% confidenceGrok 4.20 (xAI)

Will the results be positive?

Trial NCT06637254 is enrolling by invitation with primary completion estimated March 2026. No public readout available as of April 2026. Sources confirm ongoing status, no results or topline data found.

Found Apr 6, 2026, 2:59 PMReviewed Apr 6, 2026, 3:00 PM
ClinicalTrialsclinicaltrials.gov
A Study to Evaluate the Efficacy and Safety of HSK31858 Tablets in Patients with Bronchial Asthma
Phase 2 trial, current status: Enrolling by invitation, estimated primary completion 2026-03-22. No results posted.
Web Searchonlinelibrary.wiley.comOct 25, 2025, 12:00 AM
Management and Research Progress of Severe Asthma in China
HSK31858 phase 2 trial for asthma is ongoing (NCT06637254).
NO_DECISIONDismissed90% confidenceGrok 4.20 (xAI)

Will the results be positive?

NCT06637254 (Phase 2 asthma) is enrolling by invitation with estimated primary completion in Mar 2026. No public efficacy results, readout, or interpretation available for this exact trial. Positive data exists only for a separate HSK31858 Phase 2 in bronchiectasis (NCT05601778).

Found Apr 6, 2026, 2:10 PMReviewed Apr 6, 2026, 2:25 PM
Web Searchclinicaltrials.gov
A Study to Evaluate the Efficacy and Safety of HSK31858 Tablets in Patients with Bronchial Asthma
Current status: Enrolling By Invitation. Estimated Primary Completion Date: 2026-03-22. No results posted.
Web Searchonlinelibrary.wiley.comOct 25, 2025, 12:00 AM
Management and Research Progress of Severe Asthma in China
Its phase 2 trial for asthma is ongoing (NCT06637254), being expected to be a convenient oral option for T2-low asthma.
Web Searchpubmed.ncbi.nlm.nih.govJan 1, 2025, 12:00 AM
Effects of the DPP-1 inhibitor HSK31858 in adults with bronchiectasis in China (SAVE-BE)
Positive results (reduced exacerbations vs placebo) for bronchiectasis trial, not asthma.
NO_DECISIONDismissed90% confidencemanual-chat-review

Will the results be positive?

ClinicalTrials.gov still lists this study as enrolling by invitation with no posted results, so there is not yet a clear public positive or negative trial readout.

Found Apr 4, 2026, 8:54 PMReviewed Apr 4, 2026, 10:33 PM
ClinicalTrialsclinicaltrials.govDec 24, 2024, 12:00 AM
Study Details | NCT06637254 | ClinicalTrials.gov
ClinicalTrials.gov lists enrolling by invitation; primary completion 2026-03-22; hasResults=false on the latest posted update.
NO_DECISIONDismissed93% confidenceGPT-5.4 (OpenAI)

Will the results be positive?

No public asthma-trial readout was found. The cited registry lists NCT06637254 as a Phase 2 asthma study, while a later company-related disclosure says the asthma Phase 2 study was still progressing smoothly, not reporting efficacy/outcome. Positive HSK31858 data located were for bronchiectasis, a different trial/indication.

Found Apr 3, 2026, 4:30 PMReviewed Apr 3, 2026, 4:47 PM
ClinicalTrialsclinicaltrials.govOct 10, 2024, 12:00 AM
Study Details | NCT06637254 | A Study to Evaluate the Efficacy and Safety of HSK31858 Tablets in Patients with Bronchial Asthma
ClinicalTrials.gov identifies NCT06637254 as a Phase 2, randomized, double-blind, placebo-controlled asthma study of HSK31858 sponsored by Haisco.
Web Searchepaper.stcn.comSep 24, 2025, 12:00 AM
B58 信息披露 Disclosure 2025年9月24日
Company-related disclosure says HSK31858 Phase 2 studies for the asthma indication were 'progressing smoothly', which indicates ongoing development but no trial-specific positive/negative efficacy readout.
NO_DECISIONDismissed95% confidenceGPT-5.4 (OpenAI)

Will the results be positive?

No trial-specific public efficacy readout was found for NCT06637254. The registry still shows the asthma Phase 2 study with no posted results, and the sponsor pipeline lists HSK31858 for asthma as a Phase II program without outcome disclosure. That is insufficient to call positive or negative.

Found Apr 1, 2026, 7:54 PMReviewed Apr 1, 2026, 7:55 PM
ClinicalTrialsclinicaltrials.gov
Study Details | NCT06637254 | A Study to Evaluate the Efficacy and Safety of HSK31858 Tablets in Patients with Bronchial Asthma
ClinicalTrials.gov lists NCT06637254 and explicitly shows “No Results Posted” for this asthma study.
Sponsorhaisco.com
海思科医药集团 管线 / Pipeline
Sponsor pipeline lists HSK31858 for bronchial asthma among indications and keeps it at the clinical-stage pipeline level, with no trial outcome or readout stated.
Outcome History

Public history of accepted oracle reviews and recorded outcome changes for this trial.

No oracle outcome history is available for this trial yet.